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ABSTRACT
The emergence of antibiotic-resistant bacteria in the last century is alarming and calls for alternative,
nonchemical treatment strategies. Thermal medicine uses heat for the treatment of infectious diseases
but its use in facultative and obligate intracellular bacteria remains poorly studied. In this review, we
summarize previous research on reducing the infectious burden of Mycobacterium ulcerans and
Chlamydia trachomatis by using water-filtered infrared A-radiation (wIRA), a special form of heat radi-
ation with high tissue penetration and low thermal load on the skin surface. Mycobacterium ulcerans is
a thermosensitive bacterium causing chronic necrotizing skin disease. Therefore, previous data on
wIRA-induced improvement of wound healing and reduction of wound infections is summarized first.
Then, pathogenesis and treatment of infections with M. ulcerans causing Buruli ulcer and of those
with C. trachomatis infecting the ocular conjunctiva and resulting in blinding trachoma are discussed.
Both bacteria cause neglected tropical diseases and have similar geographical distributions. Results of
previous in vitro and in vivo studies using wIRA on M. ulcerans and C. trachomatis infections are pre-
sented. Finally, technical aspects of using wIRA in patients are critically reviewed and open questions
driving future research are highlighted. In conclusion, wIRA is a promising tool for reducing infectious
burden due to intracellular bacteria such as M. ulcerans and C. trachomatis.
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Bacterial infections in human patients are considered an
immediate threat to global health due to increasing anti-
biotic resistance and diminishing availability of antibiotics to
treat these infections [1]. The emergence of antibiotic-resist-
ant gram-positive and gram-negative bacteria in the last
century is alarming and calls for alternative, nonchemical
treatment strategies. Thermal medicine uses heat for the
treatment of infectious diseases and is attracting increasing
interest as an alternative or combination treatment in med-
ical microbiology. The use of thermal therapy to treat infec-
tious diseases was highlighted in a recent special issue of
the International Journal of Hyperthermia [2] and again
reviewed in a subsequent issue of this journal [3].
Thermal therapy can be used to treat local or systemic
infections and has significant advantages over antibiotic
treatment regimens when ease of use, side effects, costs,
and development of resistance are considered [2–4].
Wardlow et al. [5] combined heat with temperature-targeted
delivery of antibiotics, using low temperature sensitive lipo-
somes as a tool to enhance antimicrobial efficiency. Even
though manifold thermal therapy-related research has been
undertaken, thermal therapies mainly target extracellular
bacteria and bacterial biofilms, e.g., Pseudomonas aeruginosa
biofilms on implanted medical devices [3,4,6] or
Staphylococcus aureus-induced abscesses or biofilms in
mouse or rat models [5,7].
Thermal modalities used to combat bacterial infections
are manifold, including radiofrequency, ultrasound, high-
intensity focused ultrasound, microwave therapy, and photo-
thermal and magnetic nanoparticles [reviewed in 4]. Another
source of thermal therapy is water-filtered infrared A (wIRA),
a special form of heat radiation with high tissue penetration
and a low thermal load on the skin surface [8–10]. The high
tissue penetration of wIRA is beneficial when treating deeper
tissue layers of up to 20–30mm depth containing resident
extra- or intracellular pathogens. However, direct wIRA
effects on pathogens in vitro and in particular on obligate
intracellular infectious agents (such as chlamydiae) have not
been studied before.
As mentioned above, most thermal therapies focus on
extracellular bacteria whereas strict and facultative obligate
intracellular bacteria remain poorly studied. In an effort to
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include intracellular bacteria, and possibly other intracellular
pathogens, in the recent discussion of novel thermal therapy
approaches, we summarize results of previous research on
wIRA-induced hyperthermia as a treatment option, focusing
on Mycobacterium ulcerans and Chlamydia trachomatis.
wIRA and hyperthermia
Water-filtered infrared A (wIRA) is infrared radiation with a
spectrum of 780–1400 nm. It is produced by light from a
halogen bulb passing through a water cuvette to abate the
irradiances at 970 nm and 1160 nm, and to exclude wave-
lengths above 1400 nm. Major contributions of visible light
(VIS) can be blocked by using an optical longpass filter with
a cutoff wavelength at 590 nm [11,12], whereas black filters
block VIS (380–780 nm) entirely [13].
Clinical trials have shown that wIRA improves acute and
chronic wound healing processes and prevents wound infec-
tion [8,14–16]. In two randomized controlled trials [14,16],
the utilization of wIRA radiation and its impact on surgical
site infection in abdominal surgery was studied. Since
impaired wound healing caused by infections leads to pain,
longer hospitalization, higher costs [18], and poor cosmetic
results [8], several approaches were undertaken to reduce
the incidence of these outcomes. Beside sterile working con-
ditions and correct antibiotic prophylaxis [19], heating of the
incisional area [18] has found application, since wound repair
is influenced by tissue temperature, oxygen tension and per-
fusion [21–24]. Whole body warming [25] and heat packs
have been used to reduce wound healing impairment but
can also result in adverse effects—especially skin burns—
since heat is absorbed by the outermost skin layer (epider-
mis). One major advantage of thermal wIRA application con-
sists of its peak in warming the subcutaneous layer at about
20–30mm depth, as demonstrated by [14] in a double-
blinded postoperative protocol of local abdominal wIRA
treatment after laparotomies. The authors were able to show
a significant difference in favor of the wIRA group in four
out of five main study variables: subcutaneous oxygen partial
pressure, subcutaneous temperature and evaluation of
wound healing by the surgeon, and also a trend toward
fewer wound infections [14]. This positive outcome can be
attributed to a combination of thermal, perfusion-increasing
effects as well as nonthermal causes by direct stimulation of
cellular immunomodulation and induction of protective pro-
teins [26,27].
A second randomized control trial [16] investigated the
effect of a single, preoperative wIRA treatment in patients
undergoing median laparotomies during visceral surgery. A
total of 360 patients were randomly allocated to two
groups—treated either by a wIRA radiator or a sham lamp
for 20min before surgery. A significant reduction in wound
infection in combination with antibiotic prophylaxis could be
demonstrated (5.1%, CI: 3–9% in wIRA irradiated group vs.
12.1%, CI: 8–18%, p¼ 0.018) over a 30-day period postopera-
tively. One hypothesis suggested that wIRA therapy
improved perfusion in the subcutaneous layer—a region
where antibiotics normally reach lower serum levels [28]—
and thus results in reduced, especially superficial, surgical
site infections due to better perfusion and local distribution
of antibiotic agents.
Another field of wIRA application [29] includes the man-
agement of partial thickness skin graft transplantation. A
transplant is commonly less perfused due to its dependence
on local blood supply and also due to the lack of an intact
skin barrier, making it more prone to infections.
Local hyperthermia facilitates the reduction of the radi-
ation dose in the radiation therapy of cancer, which allows,
e.g., re-irradiations of recurrent breast cancer [30]. wIRA
could be a suitable device for achieving a homogeneous
irradiation of larger skin areas, as shown recently in a study
performed in piglets [31], while, e.g., heat packs lead to focal
hyperthermia or even skin burns without reaching therapy-
relevant temperature increases in larger skin areas or deeper
skin layers. Piazena et al. [31] allocated 11 piglets into three
intervention groups and irradiated the skin of their thighs
with different doses (irradiances) of wIRA. Skin temperatures
were measured before, during and after the wIRA irradiation
in a 1-min interval in tissue depths of 2, 4, 7, 8, 10, 12, 16,
and 20mm. The temperature measurement revealed (1) sig-
nificant individual differences between temperature profiles
and the thermoregulatory processes, (2) reproducible vertical
temperature profiles through the skin layers and subcutis,
showing the highest temperature in 4–6mm depth of the
tissue and (3) that the temperature measured at the skin sur-
face is approximately 1–2 K lower than at 4mm skin depth,
allowing an approximate estimation of the temperature
reached in deeper layers by temperature measurements at
the skin surface [31].
Further studies will be needed to assess the optimal time
and dose exposure in thermal therapies, since the mean
decay time (time after irradiation until the tissue reaches the
target temperature (e.g., 39 C) has been shown to be
dependent on irradiation dose, depth of tissue, and individ-
ual factors [31]. These are important parameters to consider
for future wIRA use in human patients, e.g., when skin treat-
ment of Buruli ulcer-affected patients is envisaged.
Buruli ulcer (Mycobacterium ulcerans disease)
Pathogenesis of Buruli ulcer
Buruli ulcer (BU), caused by infection with Mycobacterium
ulcerans, is a chronic necrotizing skin disease that primarily
affects the subcutaneous fat tissue, leading to ulceration of
the overlying dermal and epidermal layers of the skin [32].
The disease is reported from tropical regions worldwide, but
has its highest prevalence in West Africa [33], (Figure 1).
Three distinct non-ulcerative stages of the disease are
described: (i) subcutaneous, painless and movable nodules or
papules, (ii) edema, and (iii) plaques. All of them may pro-
gress to ulceration, once the destruction of the subcutis
results in collapse of the overlying epidermis and dermis
[32]. The majority of BU patients have a single skin lesion
located at the upper or lower extremities, but all body surfa-
ces can be affected [32]. Mycobacterium ulcerans has a low
optimal growth temperature of 30–33 C [34,35] and this
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temperature preference is considered a major factor for the
explicit skin tropism and the limited systemic dissemination
of M. ulcerans infections [36].
Mycobacterium ulcerans produces the polyketide exotoxin
mycolactone, which plays a key role in the pathogenesis of
BU and has cytotoxic, analgesic, and immunosuppressive
properties [37]. Exposure of different types of mammalian
cells to low nanomolar concentrations of mycolactone A/B
leads to cell death within 2–3 days [37]. While mycolactone is
produced locally by the extracellular M. ulcerans bacteria in
the skin, there is evidence that nontoxic concentrations in
the periphery induce systemic immunosuppressive activity
[38]. Macrophages and lymphocytes accumulate at the mar-
gin of the necrotic core of BU lesions, but infiltrating leuko-
cytes seem to be killed by mycolactone surrounding the M.
ulcerans clusters in the subcutaneous tissue [39]. Interference
with the production of mycolactone may thus be sufficient
for achieving therapeutic efficacy.
Treatment of BU
Traditionally, surgical treatment with wide excision margins
was the only therapeutic option for BU, as antibiotic therapy
was considered ineffective [40,41]. In most rural BU-endemic
regions of Africa, the available surgical capacity was, how-
ever, not sufficient to provide treatment for the majority of
BU patients [42]. Moreover, large excisions were not well
accepted by the patients, but were necessary to avoid
relapses [43,44]. In 2004, the World Health Organization
(WHO) published ‘Provisional guidance on the role of specific
antibiotics in the management of M. ulcerans disease’, rec-
ommending a combination therapy with oral rifampicin and
intramuscular streptomycin for eight weeks [45]. As treat-
ment with streptomycin has been shown to frequently cause
permanent ototoxicity and more occasionally transient
nephrotoxicity, the WHO Technical Advisory Group on Buruli
ulcer recommended replacing streptomycin with oral cla-
rithromycin in 2017 [46]. However, rifampicin is currently the
only highly efficacious antibiotic against M. ulcerans, and no
alternative drug treatment modality would currently be avail-
able in the case of the emergence of rifampicin-resistant
strains [40]. Repurposing of drugs under development for
tuberculosis is the most promising approach for the identifi-
cation of new antibiotics active against M. ulcerans [40], and
recent evidence indicates that the tuberculosis development
candidate Q203, could both simplify and shorten BU treat-
ment [47].
Thermosensitivity of M. ulcerans
Mycobacterium ulcerans grows optimally on bacteriological
media at 30–33 C and the viability of cultures decreases
after several days at 37 C [35]. Furthermore, it has been
found that heat exposure of the bacilli to 37 C for 1 day
retards subsequent growth at 32 C and that exposure to
41 C for 1 day kills >90% of the bacilli [48]. To gain more
Figure 1. World map showing the distribution of trachoma and Buruli ulcer (BU). Countries colored in red have reported cases of Buruli ulcer in the year 2018.
Countries colored in blue have reported trachoma cases in the year 2019 and are still considered to require intervention programs to eliminate trachoma. The pur-
ple color represents the overlap of required trachoma elimination and reported BU cases.
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information on the exposure times required for thermother-
apy, we have investigated the thermosensitivity of M. ulcer-
ans strains freshly isolated from Cameroonian BU patients
[49] in more detail. An Alamar Blue-based growth inhibition
assay adapted for the extremely slow-growing M. ulcerans
[50] was used to assess the temperature effects on metabolic
activity of the bacilli (Figure 2). Results demonstrated that
daily temperature pulses at 42 C for 20min had no marked
effect, while pulses of 1 h had moderate and 3 h had marked
effects. Pulses of up to 3 h at 37 C were ineffective. These
data indicate that for the thermotherapy of BU, short tem-
perature pulses may be ineffective.
The effects of temperature pulses on the viability of the
bacteria were analyzed by determination of the number of
colony-forming units (CFUs). A nearly complete killing of the
bacteria was achieved by five temperature pulses of three
hours at 42 C (Figure 3). While five days of permanent incu-
bation of the bacilli at 42 C led to complete eradication, five
days of incubation at 37 C had only limited effect
on viability.
Taken together, these in vitro studies indicate that for
thermotherapy of BU, heating the skin to elevated tempera-
tures (e.g., 43 C) for extended periods of time may be
required to kill the bacilli. The safety aspects of increased tis-
sue temperature, e.g., based on the CEM43 model, still
require further investigations, since biological effects of heat
therapy on normal human tissues are not entirely under-
stood [51]. However, even a reduction in the metabolic activ-
ity of the bacteria may lead to a drop in the production of
mycolactone. This may allow phagocytes to reach the bac-
teria and to contribute to the elimination of the infec-
tion [39,52,53].
Thermotherapy of BU
The thermosensitivity of M. ulcerans was first explored for
therapeutic purposes by Meyers and colleagues in the 1970s
[51]. Eight patients from Zaire were successfully treated using
circulating water jackets, maintaining a temperature of
Figure 2. Effect of temperature pulses of 37 C (A) or 42 C (B) or permanent
exposure to 30C (C) on the metabolic activity of M. ulcerans. Cultures of the
three freshly isolated [49] Cameroonian M. ulcerans strains S1012 (black bars),
S1013 (empty bars), and S1047 (grey bars) were grown in Difco Middlebrook
7H9 medium (BD), supplemented with 10% (vol/vol) Middlebrook OADC enrich-
ment medium (BD) and 0.2% (vol/vol) glycerol at 30 C in triplicate in microtiter
plates. The bacterial cultures were treated for 5 days with one temperature
pulse of 20min, one hour or three hours per day. After 2 days of recovery at
30 C, a resazurin microtiter assay adapted for the extremely slow-growing M.
ulcerans [50] was used to determine the metabolic activity of the bacteria. After
the addition of 10% (vol/vol) of a resazurin solution (0.125mg/mL, Sigma) to
the cultures and incubation for another 3 days at 30 C, end-point fluorescence
reading (Ex540nm/Em588nm) was performed. Values represent means of fluor-
escent units ± SD.
Figure 3. Effects of five daily temperature pulses of 20min or 3 h at 42 C on
the viability of M. ulcerans (shown by the mean number of colony-forming
units, (CFUs) ± SD for the three tested strains). Liquid cultures of the three
freshly isolated Cameroonian M. ulcerans strains S1012, S1013, and S1047
grown at 30 C in Difco Middlebrook 7H9 medium (BD), supplemented with
10% (vol/vol) Middlebrook OADC enrichment medium (BD) and 0.2% (vol/vol)
glycerol were exposed to temperature pulses at 42 C on five consecutive days,
then serially diluted and plated on Difco Middlebrook 7H10 agar plates (BD),
supplemented with 10% (vol/vol) Middlebrook OADC enrichment medium (BD)
and 0.2% (vol/vol) glycerol. The number of CFUs was determined after four
months of incubation of the extremely slow growing bacilli at 30 C. In add-
ition, CFU counts of cultures incubated for 5 days at 37 C or 42 C were com-
pared with a control remaining at 30 C.
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approximately 40 C in the ulcerated area for a mean dur-
ation of 68 days. No local recurrences were observed during
follow-up periods of up to 22months [54]. WHO guidelines
subsequently listed the application of heat as a treatment
option for BU (WHO 2000), but the heat application devices
employed by Meyers were impractical in rural endemic areas
of Africa and the heat treatment approach was not followed
up for more than 30 years. However, in the early 2000s, use
of commercially available silicone bags (210 155 20mm)
filled with the phase change material (PCM) sodium acetate
trihydrate, which is also widely used in commercial pocket
heat pads, was evaluated as a technical solution for thermo-
therapy of BU [55]. After initiating crystallization, the fluid
PCM maintains its melting temperature of 58 C until it has
completely solidified. For thermotherapy with the heat pads,
BU lesions and the surrounding skin were covered with ster-
ile pads, tube gauze, elastic bandage and cotton as protec-
tion and to bring the skin temperature within the
therapeutic range of 39–42 C. In a prospective observational
trial, six BU patients from Cameroon were successfully
treated for 28–55 days with the heat packs and remained
relapse-free for one and a half years after completion of
treatment [56]. A subsequent phase II clinical trial in
Cameroon under good clinical practice conditions confirmed
that thermotherapy of BU with heat packs is well tolerated
and effective [57]. Patients were treated daily with two heat
packs, with the first one being applied in the late afternoon.
Packs were changed before patients went to bed and the
second bag remained in place overnight. Heat treatment
continued for 42 days; it was terminated earlier if a lesion
had completely closed, and was extended for up to 14 days
if induration had not fully subsided [57]. In addition to the
specific effects on M. ulcerans viability, heat treatment also
appeared to promote wound healing in general.
Since wIRA enables heat application to deeper tissue
layers of the skin [14], where most M. ulcerans cells reside
[58], without overheating superficial skin layers, its use may
have the potential to bring about further improvement in
the thermotherapy of BU and might reduce the duration of
treatment required.
Chlamydial infections
Pathogenesis and treatment of trachoma
Chlamydiae are gram-negative, obligate intracellular bacteria
with a unique biphasic developmental cycle (Figure 4). In
humans, C. trachomatis is the worldwide leading cause of
sexually-transmitted bacterial infections as well as of infec-
tious blindness in developing countries. Blinding trachoma is
a devastating neglected tropical disease (NTD) affecting the
conjunctiva/cornea of human patients, especially children.
Forty-one million people suffer from active ocular C. tracho-
matis infection. Trachoma has led to visual impairment in
about 2.2 million people, of whom 1.2 million are irreversibly
blind [59].
Globally, it is estimated that blinding trachoma is endemic
in 50 countries, mainly in sub-Saharan Africa and the Middle
East, as well as in parts of Asia and South and Central
America [60] (Figure 1). Trachoma is associated with poor
hygiene status and extreme poverty [60]. The disease is
spread by direct contact with ocular and nasal discharges,
contact with fomites, or contact with eye-seeking flies
(reviewed in [61,62]). One episode of infection results in self-
limiting chlamydial conjunctivitis, an acute phase referred to
as active trachoma [63,64]. Active trachoma is usually
acquired in infancy in hyper-endemic regions and is mostly
seen in children, progressing to eyelid scarring and blindness
in adulthood [65]. Repeated and/or persistent infections trig-
ger sustained inflammation and scarring of the upper tarsal
conjunctiva. Scarring and fibrosis, in turn, distort the upper
eyelid and facilitate inturning of the eyelid (entropion) and
eyelashes (trichiasis), causing irritation of the corneal surface
and irreversible blindness due to corneal opacity (reviewed
in [61]). The immune response to C. trachomatis provides
only partial protection and does not prevent re-infection
[64], which renders the development of a vaccine against
trachoma unlikely.
A number of global health organizations have been work-
ing together to eliminate blinding trachoma by the year 2020
(WHO - SAFE strategy). The SAFE strategy includes: surgery for
trichiasis, antibiotics for active trachoma, facial cleanliness,
and environmental improvement [62,65]. The primary front-
line antibiotic used to treat ocular chlamydial infection and to
prevent trachoma is azithromycin. Current WHO recommen-
dations constitute mass treatment with a single dose of azith-
romycin [59]. Antibiotic treatment can cause unwanted side-
effects, is expensive and can lead to antibiotic resistance [64].
Although resistance to azithromycin in C. trachomatis has not
been reported so far, resistance in Streptococcus pneumoniae,
a major cause of morbidity and mortality worldwide,
increased after azithromycin mass treatment [66,67].
Experiences from genital Chlamydia control programs suggest
that early antimicrobial treatment interferes with the develop-
ment of protective immune responses [68].
Under adverse environmental conditions, developing chla-
mydiae may enter a state referred to as persistence, more
recently named the chlamydial stress response or the aber-
rant (AB) RB phenotype [61,69,70] (Figure 4). The AB form is
more resistant, or even refractory, to antibiotic treatment
[69]. Moreover, it is thought that persistence and AB forma-
tion during long-term infection also occur in vivo and that
persistent infections could cause a cascade of ongoing
inflammatory-induced sequelae resulting in scarring of the
conjunctiva and trichiasis, which cannot be reversed by anti-
biotic treatment and are associated with a higher recurrent
risk after ocular surgery [65].
In summary, despite well-supported control programs,
reported C. trachomatis cases have not reached expected
declines, re-infections are a common problem and timely
attainment of the SAFE strategy goal toward elimination of
blinding trachoma remains questionable [67,71].
Basic biology and thermosensitivity of chlamydiae
The unique biphasic life cycle of chlamydiae, including the
persistence state of development, is depicted in Figure 4.
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The intracellular life cycle and the existence of two distinct
development stages make it difficult to distinguish between
chlamydial and host cell functions or structures, and limited
knowledge is available on the temperature-sensitivity of chla-
mydiae. An increase in the incubation temperature to 42 C
can induce the so called heat shock or chlamydial stress
response [70] in C. trachomatis, which can result in complete
loss of infectivity if maintained for up to 12 or 24 h [72,73].
Apart from these specific reports, it is unknown how chlamy-
diae react to hyperthermia. Thermal effects of wIRA on chla-
mydial infections in vitro and in vivo, in the guinea pig
conjunctivitis model, have been investigated in recent stud-
ies and are summarized in sections below [74–78].
wIRA and Chlamydia—in vitro investigations
In vitro studies investigating the effects of irradiation on chla-
mydial development usually distinguish between application
of wIRA alone (780–1400 nm) or wIRA in combination with
VIS ranging from 380 to 1400 nm [74,75,76] or 595–1400
[76]. For chlamydiae, wIRA/VIS combinations have shown
additional beneficial effects compared to wIRA alone: VIS
markedly contributes to temperature increases in the sample
at high irradiation doses and extracellular chlamydial stages
(EBs) are particularly sensitive to the VIS component, whereas
mature chlamydial inclusions are not [75]. In summarizing
our previous study results, wIRA alone or wIRA/VIS combina-
tions will be summarized as ‘wIRA’ in the following sections.
For more detailed information, the reader is referred to the
specific literature cited.
Initial studies [74] investigated whether wIRA irradiation is
able to reduce intracellular mature chlamydial inclusions and
to diminish recovery of infectious EBs (Figure 4) in two differ-
ent mammalian host cell lines using a human chlamydial
strain. Since wIRA leads to temperature increase in tissue
and chlamydiae might display thermosensitivity, a tempera-
ture-controlled setting in a water-bath set to 37 C was
chosen to avoid bacterial heat-shock responses or
Figure 4. Developmental cycle of Chlamydia including the extracellular, infectious elementary body (EB), the intracellular replicating reticulate body (RB) and the
persistent aberrant body (AB) induced by stress conditions. wIRA treatment at different timepoints of the developmental cycle has shown reductive effects on chla-
mydial infectivity.
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overheating of the host cells [74]. In the latter study, a
diminished recovery of chlamydia upon wIRA irradiation was
demonstrated, without leading to the chlamydial stress
response (persistence) or causing detrimental effects on
host cells.
Using a temperature-controlled setting, Marti et al. [74]
determined a temperature rise of the intra-well temperature
during the 20 min irradiation period at a dose of 370mW/
cm2. During the first 5min of irradiation, a rise from 34.7 C
to 37.6 C was measured, reaching a stationary phase after
10min at 38.4 C, and did not exceed 38.8 C within the
20 min irradiation period. In nonirradiated controls, the tem-
perature at the bottom of the well ranged between 35.1 and
35.9 C within the 20min time frame. Mimicking the tem-
perature rise by setting the water bath to 41 C for 20min
resulted in the same temperature profile as measured during
irradiation. This temperature increase reduced the chlamydial
inclusion frequency to a similar extent (0.41 inclusion per
nucleus) as the single-dose irradiation (0.47 inclusion per
nucleus). Therefore, Marti et al. [74] concluded that thermal
effects on Chlamydia due to irradiation are involved in the
reduction of chlamydial infectivity.
A follow-up study [75] aimed to investigate factors influ-
encing the effects of wIRA on acute chlamydial infection,
namely the impact of temperature, exposure intensity, infec-
tious dose as well as the efficacy of the VIS component.
Cultures were exposed to wIRA for 20min in a temperature-
controlled setting maintaining 37 C. This study showed that
not only thermal but also nonthermal effects may contribute
to the inhibition of acute chlamydial infection. The water
bath temperature was lowered to 34 C resulting in an intra-
well temperature on top of the coverslip of approximately
36 C, which was identical to that of nonirradiated control
wells at a water bath temperature of 37 C. The reduction of
IFU/mL following irradiation in a temperature-controlled set-
ting (water bath at 34 C) was similar to that of irradiation at
a water bath temperature set at 37 C. Regardless of the
infectious dose, wIRA irradiation reduced the infectivity of
EBs in an irradiation dose-dependent manner. Surprisingly,
the reduction of infectivity of mature chlamydial inclusions
was not only independent of the chlamydial infectious dose
(as irradiation of EBs) but also remained the same regardless
of the wIRA irradiation intensity [75]. The latter finding sug-
gests a contribution of host cell factors to the anti-chlamyd-
ial effect at a late stage of the chlamydial developmental
cycle [75].
These preliminary results encouraged us to further evalu-
ate wIRA as a possible non-chemical treatment method for
blinding trachoma by studying wIRA effects in an ocular
in vitro infection model (ocular strain C. trachomatis serovar
B and human conjunctival epithelial cells (HCjE)) and nonin-
fected ocular structures in two ex vivo eye models [76]. In
vitro, wIRA was applied for 30min in the temperature-con-
trolled setting (37 C) as described previously [74,75].
Irradiation with wIRA was carried out on infected HCjE cells
at 40 h p.i. (mature chlamydial inclusions, first setting) or cell
monolayers were irradiated at 8, 6, 3 h, and immediately
before infection with EBs, which had also been either
irradiated or not (second setting). A significant wIRA-induced
reduction of C. trachomatis serovar B infectivity in HCjE could
be observed: a single dose of wIRA reduced the number of
mature chlamydial inclusions at 43 h p.i. by 35.2%
(780–1400 nm) and by 53.8% (595–1400 nm). The combined
irradiation of cells (four times) and EBs prior to infection had
a strong synergistic effect, leading to a decrease in chlamyd-
ial infectivity of 73.5% (780–1400 nm) and 86.9%
(595–1400 nm) of the control, respectively. Moreover, wIRA
treatment of HCjE prior to chlamydial infection was sufficient
to inhibit chlamydial infectivity, indicating the induction of
potential protective effects in wIRA-treated cells possibly via
increasing their cell metabolism, since wIRA neither reduced
HCjE cell viability nor induced retinal damage post-treatment,
thus excluding potential harmful effects. In addition, temper-
atures during wIRA exposure did not markedly exceed
physiological eye temperatures at relevant doses (200mW/
cm2), suggesting that hyperthermia-related lesions are
unlikely [76].
Previous investigations [74] using a triple dose irradiation
of wIRA (370mW/cm2, 380–1400 nm) for 20min of C. tracho-
matis-infected HeLa cells revealed a release pattern of a sub-
set of pro-inflammatory cytokines and chemokines after
chlamydial infection, irradiation, and the combination of
both, but not in a synergistic manner. These findings were
further evaluated in a subsequent study [77] showing that
wIRA-induced reduction of chlamydial infectivity is independ-
ent of targeted cytokine inhibition of IL-6, IL-8, or RANTES/
CCL5, either by pharmacological inhibition or by transfection
with corresponding siRNAs. Conversely, wIRA acts reductively
on chlamydial infection without influencing the host cyto-
kine/humoral immune response, as recently confirmed by a
guinea pig inclusion conjunctivitis study in vivo [79].
In vivo data and translation to the clinical setting
Convincing in vitro results demonstrating that exposure of
Chlamydia-infected cells to wIRA irradiation reduces: (1) the
number of chlamydial inclusions that develop, and (2) the
production of infectious chlamydiae without any negative
impacts on host cell viability [74,75] prompted us to further
investigate the effect of wIRA in an experimental animal
model. The guinea pig inclusion conjunctivitis induced by
experimental C. caviae infection is an established model of
trachoma-like disease [80,81] and was applied to test the
effect of wIRA in an ocular in vivo model [79]. To study the
acute course of a primary infection, Hartley strain guinea
pigs were infected with 1 106 inclusion-forming units (IFUs)
per eye of C. caviae directly into the conjunctival sac on day
0. In infected animals, wIRA was applied for 30min on day 2
(single treatment) and on days 2 and 4 (double treatment)
p.i. [79]. In this model, wIRA reduced the pathology score on
days 7 and 14 p.i. and the chlamydial load on days 2, 4, 7
and 14 p.i. in comparison with C. caviae-infected, nonirradi-
ated control animals. On day 21 p.i., the number of chlamyd-
ial inclusions was reduced in singly and doubly treated
animals, and PMNs were significantly reduced in the eyelids
of animals treated on days 2 and 4 p.i. In general, a double
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treatment with wIRA/VIS (days 2 and 4 p.i.) was more effi-
cient than a single treatment on day 2 p.i. The IFN-c values
in tear washes (days 0, 4, 7, 14, and 21 p.i.) and C. caviae-
specific IgG antibodies in serum samples (days 0 and 21 p.i.)
did not differ between infected, non-irradiated and infected,
irradiated (single or double treatment) animals, but followed
the course of C. caviae infection and the pathology scores.
The latter is in line with recent in vitro findings [77] showing
that certain cytokines and chemokines are not involved in
the wIRA working mechanism. As seen in vitro [74,76,77], it is
likely that nonthermal as well as thermal effects play a role
in reducing chlamydial burden and infectivity. The latter
would consist of a temperature rise in the conjunctival lid
surfaces and on the cornea, possibly also affecting other ocu-
lar structures. Preliminary unpublished investigations of ocu-
lar wIRA application in anesthetized pigs were conducted,
irradiating them under general anesthesia through closed
eyelids with a temperature probe placed on the cornea. The
temperatures measured on the cornea of these six pigs
ranged from 36.8 to 38.6 C with a mean value of 37.5 C. In
the guinea pig study [79], probes were inserted between the
conjunctiva and the cornea to measure the temperature dur-
ing wIRA/VIS treatment (30min, 210mW/cm2). Temperatures
ranged from 37.5 to 37.9 C on day 2 and from 37.5 to
37.8 C on day 4 of wIRA treatment, indicating that heat pro-
duced by wIRA was mainly absorbed by the guinea pig
lid tissue.
wIRA-induced hyperthermia is of benefit in treating chla-
mydial infections in the conjunctiva, but might be critical
when other ocular structures are reached. Recent data from
our laboratory showed that wIRA (100mW/cm2,
595–1400 nm for 30min) does not activate markers of cyto-
toxicity such as phosphorylated p38, Akt, Erk, or SAPK/JNK in
the highly photo- and heat-sensitive retinae of adult and
postnatal (10 days old) mice at 0, 3, and 24 h after irradiation
at 37 C [76]. The latter study also investigated the vitreal
temperature, which can affect the neighboring thermo- and
photosensitive retina, in an ex vivo perfused pig eye model
in which the vitreal temperature was adjusted to 34 C
(physiological temperature). The temperature during irradi-
ation was measured in the middle of the vitreous body or
on top of the cornea during a 30min irradiation by wIRA at
different doses and wavelengths [76]. The vitreal temperature
increased to 38.4 C after 30min with an irradiation dose of
370mW/cm2, which was, however, a higher dose than that
used in the aforementioned guinea pig model (210mW/
cm2) [79].
In human ophthalmology, temperatures of up to 40 C are
induced at the internal lid surface by commercial heat ther-
apy devices (e.g., LipiFlow) for melting obstructed meibum in
patients with recalcitrant Meibomian gland dysfunction [82].
However, it is well known that the retina and the adjacent
retinal pigment epithelium are sensitive to changes in tem-
perature and intraocular pressure. Thus, the risk for damage
to the neural visual system increases with long irradiation
durations (e.g., 30min). Therefore, ocular safety studies in a
guinea pig or pig experimental model will be needed to
exclude any deleterious effect of wIRA on sensitive ocular
structures such as the cornea, lens, vitreous body, and retina.
Moreover, short-term irradiation protocols (5 or 15min)
including multiple doses would be preferable to apply in the
target population (mainly children).
Discussion, conclusion, future directions
Drawbacks in treatment of NTDs
Blinding trachoma and BU are devastating NTDs affecting
the conjunctiva/cornea and skin/subcutaneous tissue of
human patients, in particular children. Trachoma and BU
have similar geographical distributions and are most preva-
lent in Sub-Saharan Africa (Figure 1). Trachoma, caused by
ocular serovars of C. trachomatis, and BU, induced by M.
ulcerans, is commonly treated with antibiotics. The SAFE
strategy to eradicate blinding trachoma by 2020 includes a
single dose of oral azithromycin [59]. To date, antibiotic
treatment as part of the SAFE strategy has not produced the
desired results, leaving a considerable number of people still
infected despite therapy [71,83]. Antimicrobial treatment
using rifampicin and streptomycin for eight weeks is the cur-
rent WHO-recommended therapy for BU [45]. BU treatment
with rifampicin and streptomycin is associated with severe
side effects and cannot be easily decentralized because
streptomycin has to be injected daily. The drawbacks of anti-
biotic treatments are manifold, and growing antibiotic resist-
ance is a worldwide threat [84]. Development of a safe and
effective C. trachomatis vaccine remains an ultimate goal, but
short-term immunity and immunopathology induced by vac-
cination remains a critical hurdle [85]. Vaccine development
for BU is hampered by incomplete knowledge of the nature
of immune defenses needed to control the infection, mean-
ing that no vaccine candidate is currently in advanced devel-
opment. Therefore, alternative nonchemical therapeutic
strategies are urgently needed to combat these diseases
caused by intracellular bacteria.
Thermotherapy using wIRA as promising
treatment option
Thermotherapy has been shown to be clinically effective in
several skin diseases, such as BU and leishmaniasis, but is
not yet broadly applied. wIRA is a noninvasive source for
safe thermal therapy and, in contrast to many drug treat-
ments, is free of severe side effects requiring hospital-based
treatment. Using wIRA would allow applying treatment at
peripheral health centers close to patient communities,
which would substantially lower the economic burden for
the affected impoverished populations in the endemic trach-
oma and BU areas. wIRA radiators are easy to use devices
that do not require a particular environment or skilled med-
ical personnel and could be placed in remote areas (villages)
without a power supply and used as an ambulant therapy.
The irradiation device is affordable and does not need any
expensive maintenance [86]. Limited access to hospitals and
lack of resources to finance transport and costs of hospital
stays are a major cause of the delayed reporting of patients
380 N. BOREL ET AL.
to the formal health systems. Therefore, there is an urgent
requirement to bring treatments closer to the affected com-
munities. wIRA treatment is highly suitable for achieving this
goal: its application is not harmful, which renders it practical
in settings where rapid laboratory reconfirmation of clinical
diagnosis is not readily available. wIRA is applicable in areas
without electricity through rechargeable batteries and a port-
able generator. The mobile wIRA irradiators are easily man-
ageable and almost maintenance-free medical devices.
Previous in vitro, ex vivo, and animal model data have
demonstrated the efficacy of wIRA against chlamydial and
mycobacterial infections. Thus, the next logical step would
be to implement wIRA as an innovative treatment for trach-
oma and BU in affected individuals. As a non-chemical treat-
ment, wIRA does not interact with other therapeutic
strategies such as antimicrobial substances or vaccines. Thus,
it can be applied as an exclusive treatment, but also in com-
bination with established antibiotic treatment strategies. The
application of wIRA might thus reduce antibiotic use and the
incidence of antimicrobial resistance. Inappropriate or incon-
sistent antibiotic therapy is a primary factor leading to resist-
ance, which is particularly problematic in developing nations
where antimicrobials can be acquired only periodically and
where use of expired or counterfeit medications is common
[87]. wIRA could represent an important aid in overcoming
such limitations. Moreover, wIRA might be suitable not only
to treat existing infections but also to reduce re-infections,
transmission of disease and disease progression.
Future directions
Chlamydia trachomatis infection occurs mainly in children
aged 1–5 years, who act as a reservoir for the bacterium and
will be the target population for treatment. In children,
potential wIRA treatment is best applicable as a single short-
term irradiation. Therefore, the efficiency of single short-term
irradiations (5 or 15min) needs to be evaluated in future
experiments.
Chronic/persistent C. trachomatis infections may contrib-
ute to prolonged, chronic inflammation, fibrosis, and scarring
through continuing stimulation of the host immune system,
as seen in trachoma [65]. The conjunctival epithelium is an
immunocompetent tissue in which infection induces IFN-c,
increasing the likelihood that IFN-c-mediated persistence/
stress is also present in C. trachomatis-infected ocular tissues
[88,89]. Previous in vitro studies have not addressed chronic/
persistent chlamydial infection. Therefore, it remains to be
investigated whether wIRA is effective against chronic/per-
sistent C. trachomatis infection and if it is also able to reduce
EB recovery after persistence.
In conclusion, once successfully implemented for BU and/
or trachoma, it might be possible to extend the spectrum of
wIRA-treatable tropical skin diseases, since there is evidence
that other pathogens, such as the obligate intracellular
protozoa of the genus Leishmania are sensitive to heat [90].
Such an integrated approach is in line with the new WHO
strategy to promote an integrated strategy for skin-related
NTDs that require active detection, treatment and con-
trol [91].
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